| __timestamp | Axsome Therapeutics, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 10337679 |
| Thursday, January 1, 2015 | 2419289 | 18187286 |
| Friday, January 1, 2016 | 6343648 | 24758063 |
| Sunday, January 1, 2017 | 7206691 | 23666957 |
| Monday, January 1, 2018 | 9351522 | 30099855 |
| Tuesday, January 1, 2019 | 13598030 | 64947625 |
| Wednesday, January 1, 2020 | 28896749 | 186363444 |
| Friday, January 1, 2021 | 66646205 | 272611040 |
| Saturday, January 1, 2022 | 159253661 | 358782000 |
| Sunday, January 1, 2023 | 323123000 | 409864000 |
| Monday, January 1, 2024 | 411359000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and Axsome Therapeutics, Inc. over the past decade. From 2014 to 2023, Intra-Cellular Therapies saw a staggering 3,860% increase in SG&A expenses, peaking at approximately $410 million in 2023. Meanwhile, Axsome Therapeutics experienced a remarkable 23,000% surge, reaching around $323 million in the same year.
This trend highlights the aggressive expansion and operational scaling these companies have undertaken. Notably, the sharp rise in expenses from 2020 onwards reflects strategic investments in marketing and administrative capabilities, essential for sustaining growth in a rapidly evolving market. As these biotechs continue to innovate, understanding their cost structures offers valuable insights into their financial health and strategic priorities.
AbbVie Inc. vs Axsome Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Intra-Cellular Therapies, Inc.
Novartis AG or Axsome Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Sanofi and Axsome Therapeutics, Inc.
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Axsome Therapeutics, Inc.
Intra-Cellular Therapies, Inc. or Pharming Group N.V.: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Catalyst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and MannKind Corporation
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
Axsome Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared